Stay updated with breaking news from Nasdaq fulc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Fulcrum Therapeutics, Inc. (NASDAQ:FULC – Get Free Report) was the recipient of some unusual options trading on Monday. Stock traders purchased 21,436 call options on the company. This is an increase of approximately 9,180% compared to the average volume of 231 call options. Insider Buying and Selling at Fulcrum Therapeutics In other Fulcrum Therapeutics news, […] ....
Fulcrum Therapeutics, Inc. (NASDAQ:FULC – Get Free Report) VP Greg Tourangeau sold 4,884 shares of the company’s stock in a transaction that occurred on Friday, March 8th. The shares were sold at an average price of $11.72, for a total value of $57,240.48. Following the completion of the transaction, the vice president now owns 11,807 […] ....
Fulcrum Therapeutics (NASDAQ:FULC – Free Report) had its price objective upped by Piper Sandler from $13.00 to $15.00 in a research note published on Wednesday morning, Benzinga reports. Piper Sandler currently has an overweight rating on the stock. Separately, The Goldman Sachs Group lifted their price target on shares of Fulcrum Therapeutics from $5.00 to […] ....
Fulcrum Therapeutics (NASDAQ:FULC – Get Free Report) had its price objective hoisted by stock analysts at Piper Sandler from $13.00 to $15.00 in a report issued on Wednesday, Benzinga reports. The firm presently has an “overweight” rating on the stock. Piper Sandler’s target price indicates a potential upside of 39.15% from the stock’s previous close. […] ....
Fulcrum Therapeutics (NASDAQ:FULC – Get Free Report) and Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, earnings, analyst recommendations, valuation and profitability. Earnings and Valuation This table compares Fulcrum Therapeutics […] ....